Standard BioTools Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Standard BioTools Inc. (LAB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.17 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- Standard BioTools Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.25, a 9.76% increase year-over-year.
- Standard BioTools Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.05.
- Standard BioTools Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.00.
- Standard BioTools Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $0.00.
- Standard BioTools Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.17, a 53.20% decline from fiscal 2024.
- Standard BioTools Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.50, a 2.72% decline from fiscal 2023.
- Standard BioTools Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.57, a 34.27% decline from fiscal 2022.
- Standard BioTools Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.91, a 29.68% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.17 10-K · filed 2026-03-16 | |||
| 2024-12-31 | $2.50 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $2.50 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $2.50 10-Q · filed 2024-08-06 | |||
| 2024-03-31 | $2.25 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $2.57 10-K · filed 2024-03-01 | |||
| 2023-09-30 | $2.57 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $2.61 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $2.05 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $3.91 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $3.91 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $3.91 10-Q · filed 2022-08-09 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $5.56 10-K · filed 2023-03-14 | |||
| 2021-09-30 | $5.56 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $5.56 10-Q · filed 2021-08-06 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $4.05 10-K · filed 2022-03-08 | |||
| 2020-09-30 | $3.74 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | $3.74 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $13.08 10-K · filed 2022-03-08 | |||
| 2019-09-30 | $13.08 10-Q · filed 2019-11-08 | |||
| 2019-06-30 | $13.41 10-Q · filed 2019-08-07 | |||
| 2018-12-31 | $6.05 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $5.61 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $7.44 10-K · filed 2019-03-18 | |||
| 2015-12-31 | $29.60 10-K · filed 2016-02-29 | |||
| 2014-12-31 | $43.09 10-K · filed 2015-02-26 | |||
| 2013-12-31 | $18.13 10-K · filed 2014-03-12 | |||
| 2012-12-31 | $14.86 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |